Medullary thyroid gland carcinoma
MONDO:0015277A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis. Surgery is the preferred treatment for both primary lesions and recurrences. This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.
Also known as: C cell carcinoma, MTC, carcinoma of parafollicular cell, carcinoma, C-cell, malignant, medullary carcinoma, medullary carcinoma of the thyroid, medullary carcinoma of the thyroid gland, medullary carcinoma of thyroid
2831 clinical trials for this condition and its sub-types, 42 tagged with Medullary thyroid gland carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Medullary thyroid gland carcinoma
-
Familial medullary thyroid carcinoma 23 trials
-
New pill targets Hard-to-Treat cancers after other drugs fail
Disease control CompletedThis early-stage trial is testing an oral drug called LOXO-260 in about 70 people with advanced cancers that have a specific change in the RET gene. The cancers have stopped responding to other targeted treatments. The study aims to find the safest dose and see if the drug can sh…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Targeted drug regorafenib tested in rare thyroid cancer
Disease control CompletedThis phase II study tests the targeted therapy regorafenib (Stivarga) in 8 people with metastatic medullary thyroid cancer that has progressed after prior treatment. The drug aims to block cancer growth by targeting specific proteins. Researchers are measuring how long participan…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New radiation approach may reduce side effects in breast cancer treatment
Disease control CompletedThis study compared two radiation methods for people with early-stage breast cancer: a shorter, more focused radiation (accelerated partial breast irradiation) versus standard whole breast radiation. The goal was to see which causes fewer side effects like skin problems, breast s…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New pill shows promise in slowing rare thyroid cancer
Disease control CompletedThis phase 3 trial tested a daily oral drug called vandetanib (ZD6474) against a placebo in 331 people with advanced medullary thyroid cancer that could not be removed by surgery. The main goal was to see if the drug could delay tumor growth. Researchers also measured how many pa…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New PET tracer could spot hidden thyroid cancer
Diagnosis CompletedThis study tested whether a special PET scan tracer called 18F-DOPA can better detect leftover medullary thyroid cancer in lymph nodes after surgery, compared to standard imaging. Twenty-four adults with elevated thyrocalcitonin levels (a sign of residual disease) received the tr…
Sponsor: Institut Claudius Regaud • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
Thyroid cancer patients may spend less time in discomfort with simple phone calls
Symptom relief CompletedThis completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults…
Phase 3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC